Evaluation and Treatment of Pain in Fetuses, Neonates and Children

Santiago Mencía, Clara Alonso, Carmen Pallás-Alonso, Jesús López-Herce and Maternal and Child Health and Development Network II (SAMID II)

Abstract: The perception of pain is individual and differs between children and adults. The structures required to feel pain are developed at 24 weeks of gestation. However, pain assessment is complicated, especially in neonates, infants and preschool-age children. Clinical scales adapted to age are the most used methods for assessing and monitoring the degree of pain in children. They evaluate several behavioral and/or physiological parameters related to pain. Some monitors detect the physiological changes that occur in association with painful stimuli, but they do not yet have a clear clinical use. Multimodal analgesia is recommended for pain treatment with non-pharmacological and pharmacological interventions. It is necessary to establish pharmacotherapeutic protocols for analgesia adjusted to the acute or chronic, type and intensity of pain, as well as age. The most used analgesics in children are paracetamol, ibuprofen, dipyrone, opioids (morphine and fentanyl) and local anesthetics. Patient-controlled analgesia is an adequate alternative for adolescent and older children in specific situations, such as after surgery. In patients with severe or persistent pain, it is very important to consult with specific pain services.

Keywords: analgesia; pain; children; analgesics; behavioral pain assessment; pain scales

1. Introduction

Pain can be defined as “an unpleasant sensory and emotional experience associated with actual or potential tissue damage or described in terms of such damage” [1]. Pain consists of two features: nociception and emotional reaction.

Perception of pain is individual and differs between children and adults. The sensation of pain is not only influenced by neurophysiological mechanisms but also by both psychological aspects and the environment [2]. These aspects affect and modulate the nociceptive sensation so that the same pathological situation may cause very different painful perceptions depending on the individual. In general, children pay maximum attention to pain, which could lead increased anxiety and fear of the painful sensation, magnifying the sensory experience [3,4].

Therefore, different pain management strategies are required in children than in adults, highlighting the importance of prior preparation and non-pharmacological interventions before performing any painful procedure in a child [5,6] (Table 1).
Table 1. Pain differences according to age.

|                                | Neonates and Infants | Children | Adults |
|--------------------------------|----------------------|----------|--------|
| Development of pain sensitivity| Yes, undefined       | Yes, defined | Yes, defined |
| Location of pain               | No                   | No; Yes in older children | Yes    |
| Verbal expression              | Cry                  | Verbal; Could be non-specific | Verbal and specific |
| Pain response                  | Important and generalized (tachycardia, tachypnea, hypertension–hypotension, severe stress and agitation) | Important in toddlers; Moderate in older children | Mild |
| Difference between anxiety and pain | No                  | Only older children | Yes    |
| Clinical evaluation            | Physiological scales | Physiological and verbal scales, non-numerical | Numerical scales |
| Analgesic drugs                | Very few studies; Empirical off-label treatment for most drugs; Undefined doses | Few studies; Empirical off-label treatment for most drugs | Many studies; Well-defined doses |
| Side effects of analgesic drugs| Severe systemic side effects (bradycardia, hypotension and respiratory arrest) Psychomotor development effect? | Moderate systemic side effects Psychomotor development effect? | Mild systemic side effects |

2. Fetal Pain

2.1. Fetal Pain

Pain is a conscious and subjective experience and not just a response to noxious stimuli. For human beings to be able to experience pain, a series of physiologically mature neurological structures is needed. On the other hand, for the experience of pain to occur, other cognitive processes related to the state of consciousness and memory must be developed, which, in turn, allow an event to be discriminated as painful [7–11].

The development of neural pathways involved in pain pathophysiology begins early in fetal life, around the seventh week of gestation, followed by the development of the thalamus and neural connections in the cerebral cortex [7–9]. Therefore, some authors suggest that fetal pain does not occur before 24 weeks of gestation because the structures of the central nervous system (CNS) required for pain perception, such as the cortex, spinal cord and thalamus are not fully developed [10]. However, other authors argue that pain perception can occur, mediated by developmental structures, such as the subplate, between 12 and 20 weeks of gestation [11–14]. Additionally, behavioral changes associated with pain, such as simple motor responses, including crying and facial expressions, are described in fetuses and very premature neonates [15,16].

2.2. Fetal Pain Evaluation

Several physiological reactions in fetuses, such as crying, avoidance or changes in the levels of stress hormones, can be interpreted as signals of pain.

Magnetic resonance imaging (MRI) and fetal magnetoencephalographic imaging showed evoked responses to vibroacoustic and visual stimuli in the third trimester [17–19].

Ultrasound investigation has enabled the acquisition of behavioral characteristics in fetuses, such as crying [20,21], as well as fetal facial expressions of acute pain in surgery [22], as well as fetal movement in response to contact with an amniocentesis needle [23].
Fetuses exposed to a prolonged painful invasive procedures have increased concentrations of cortisol and beta endorphins in plasma [24,25].

2.3. Treatment of Fetal Pain in Fetal Surgery

Treatment of fetal pain is especially significant in fetal surgery. There are three main administration routes of fetal anesthesia and analgesia: uteroplacental transfer; intravenous, usually by the umbilical line; or intramuscularly [26]. Volatile anesthetics and opioids limit the fetal stress response, although they can produce cardiovascular fetal depression, although likely without side effects for short procedures [27].

Most authors use deep general maternal anesthesia in ex-tero intrapartum therapy surgery to anesthetize the mother and the fetus and in fetoscopies the preferences are administer the anesthesia and analgesia directly to the fetus, usually applying an intramuscular route or umbilical line [28–36].

3. Neonatal Pain

After painful stimulus, newborns have demonstrated in MRI scans that brain regions encoding sensory and affective components of pain responses are similar to those in adults [37].

Excessive or maintained pain exposure can be detrimental, causing adverse physiological effects and even long-term consequences [38–40]. Preterm infants, after experiencing pain, were reported to suffer hyperalgesia and allodynia, producing prolonged stress [41].

Infants born very preterm (<32 weeks), have received many pain-related insults in a vulnerable cerebral period, require special attention [38]. Repeated pain-related stress in very premature newborns is associated with alteration of brain development during the neonatal period, [42] as well as later functional cortical activity impairment with thinning of the brain cortex, white matter microstructure alterations and cognitive outcome at school age [43,44].

4. Pain in Children

Children usually feel pain differently than adults. The American Academy of Pediatrics (AAP) and the American Pain Society provided a general definition of pediatric pain: “the concept of pain and suffering goes far beyond a simple sensory experience. There are emotional, cognitive and behavioral components, along with developmental, environmental and sociocultural aspects” [45]. This definition underlines the importance of the subjectivity of pain [46]. Fear and anxiety produce suffering and increase the perception of pain in children, especially the fear of separation from their parents. An important goal of pain management is to eliminate the suffering associated with pain.

5. Pain Assessment

5.1. Concepts

The first step in the treatment of pain is its detection; several circumstances must first be taken into account:

- The characteristics of the child: age, sex, sociocultural level and mood.
- The characteristics of the pain: form of onset, intensity, evolution, duration, etiology and consequences that may be triggered [47].

The assessment of pain in children is complex, specifically in neonates, infants and preschool-aged children, because the expression of pain is undifferentiated, so it is often not possible to distinguish between pain, irritability and anxiety. Because they are not verbal, pain assessment tools rely on surrogated measures of physiologic, behavioral and biobehavioral responses to pain.

The most frequent physiologic indicators of pain are changes in heart and respiratory rate, blood pressure and oxygen saturation. The use of vital signs alone is not adequate because neonates and infants cannot maintain an autonomic response to pain and other
factors, such as mechanical ventilation and drugs [48]. These indicators are also affected by other physiological stimuli, such as hypovolemia or fever.

The most used indicators are crying, facial activity, body movements, resting positions, agitation, consolability and sleeplessness. The assessment of these behavioral indicators depends on gestational age, mechanical ventilation and pharmacological treatment, and neurologic impairment and neuromuscular blockade may also decrease or alter responses to pain in critically ill children.

5.2. Neonatal Pain Assessment Tools

Several neonatal pain assessment tools are available [49–51]. Only three pain scales, PIPP-R, N-PASS and BPSN, are adapted to premature infants. The most commonly used pain scales are summarized in Table 2 [48,52]. Pain assessment tools should be selected with consideration of the population (full-term vs. preterm), context and type of pain (procedural vs. postoperative) [51,52].

Table 2. Neonatal pain scales.

| Pain Scale                                      | Gestational Age       | Parameters                                                                 | Type of Pain                        | Scale Metric |
|------------------------------------------------|-----------------------|---------------------------------------------------------------------------|-------------------------------------|--------------|
| PIPP-R (premature infant pain profile-revised) | 26 weeks to term      | Heart rate and oxygen saturation. Alertness, brow bulge, eye squeeze and nasolabial furrow | Procedural and postoperative        | 0–21         |
| CRIES (cries, requires oxygen, increased vital signs, expression, sleeplessness) | 32–56 weeks           | Blood pressure, heart rate, oxygen saturation. Cry, expression and sleeplessness | Postoperative                       | 0–10         |
| NIPS (neonatal infant pain scale)              | 28–38 weeks           | Breathing pattern. Facial expression, cry, arms, legs and alertness       | Procedural                          | 0–7          |
| COMFORT neo                                    | 24–42 weeks           | Respiratory response, blood pressure and heart rate. Alertness, agitation, physical movements, muscle tone and facial tension | Prolonged                           | 8–40         |
| NFCS (neonatal facial coding system)           | 25 weeks to term      | Brow bulge, eye squeeze, nasolabial furrow, open lips, stretched mouth, lip purse, tau tongue and chin quiver | Procedural                          | 0–10         |
| N-PASS (neonatal pain, agitation and sedation scale) | 0–100 days           | Heart rate, respiratory rate, blood pressure and oxygen saturation. Crying or irritability, behavior state, facial expression, extremities or tone | Acute and prolonged pain. Also assesses sedation | Pain 0–10 Sedation −10–0 |
Table 2. Cont.

| Pain Scale | Gestational Age | Parameters | Type of Pain | Scale Metric |
|------------|-----------------|------------|--------------|--------------|
| EDIN (échelle de la douleur inconfort nouveau-né) | 25–36 weeks | Facial activity, body movements, quality of sleep, quality of contact with nurses and consolability | Prolonged | 0–15 |
| BPSN (Bernese pain scale for neonates) | 27–41 weeks | Respiratory pattern, heart rate and oxygen saturation. Alertness, duration of cry, time to calm, skin color, brow bulge with eye squeeze and posture | Procedural | 0–27 |

Most tools adequately assess acute pain but not persistent or prolonged pain. Only two scales are adequate for prolonged pain (N-PASS and EDIN) [53]. The COMFORTneo scale was reported to be useful for evaluation of prolonged pain in [48].

Most parameters evaluated by these tools are subjective and require observation and recording in real time.

Other tools, such as neuroimaging (functional magnetic resonance imaging and near-infrared spectroscopy) and neurophysiologic techniques (amplitude-integrated electroencephalography, changes in skin conductance and heart rate variability) during acute or prolonged pain, were studied in [44,51]. Hormonal markers of stress, such as cortisol and parameters of oxidative stress, increase with pain stimuli, but they are not used in clinical settings at this time.

5.3. Pain Assessment Tools for Children
5.3.1. Clinical Scales

Clinical scales are the most commonly used instruments for pain assessment and monitoring [54]. The most frequently used are numerical, visual analogue or graphic scales adapted to the patient’s age. Through these scales, the patient can indicate the intensity of pain or the observer estimates the pain intensity based on the child’s behavior.

In the preverbal stage (1 month to 3 years), the scales mainly use facial expression and motor and physiological responses, such as crying. In the verbal stage (3 to 8 years) self-report can be tested using photographs and drawings of faces. From the age of 8 years onwards, verbal scale, numerical scale and graphic scales, as well as the visual analogue scale, can be used [55–57].

The most commonly used scales for the assessment of pain in child who are able to communicate are:

1. The visual analogue scale (VAS), which is represented on a 10 cm line between 0 (no pain) and 10 (worst pain imaginable). VAS < 4 indicates mild or mild–moderate pain, 4–6 indicates moderate–severe pain and >6 indicates severe pain.
2. The verbal numeric scale (VNS): the child expresses their perception of pain from 0 (no pain) to 10 (worst pain imaginable).
3. Graphic scales, which may consist of drawings of happy faces that change to sad according to the degree of pain, columns or thermometers that are more or less filled in, color ranges, etc.

In most children admitted to pediatric intensive care units (PICUs), it is not possible to use such scales, as many of the patients are sedated and unable to communicate. The same applies to children under 3 years of age in the preverbal stage. In such cases, the
identification of pain requires tools based on changes in physiological parameters, facial expression or motor response to estimate the degree of pain [54,58].

Two scales have been validated for use in critically ill children:

1. The FLACC scale (face, leg, activity, cry, consolability) (Table 3), which considers facial expression, leg attitude, spontaneous activity, the presence and characteristics of crying and the ability to comfort or consolability, with scores ranging between 0 and 2 points for each item. A value of 0 indicates no pain, and scores of 9–10 indicate unbearable pain.

| Face         | 0                      | 1 | 2 |
|--------------|------------------------|---|---|
| Face         | No particular expression or smile | Occasional grimace or frown, withdrawn, disinterested. | Frequent to constant quivering chin, clenched jaw |
| Legs         | Normal position or relaxed | Uneasy, restless, tense | Kicking or legs drawn up |
| Activity     | Crying quietly, normal position, moves easily. | Squirming, shifting back and forth, tense. | Arched, rigid or jerking. |
| Cry          | No cry (awake or asleep) | Moans or whimpers; occasional complaint. | Crying steadily, screams or sobs, frequent complaints. |
| Consolability| Content, relaxed.       | Reassured by occasional touching, hugging or being talked to; distractible. | Difficult to console or comfort. |

No pain, 0; mild pain, 1–2; moderate pain, 3–5; severe pain, 6–8; extreme–maximum pain, 9–10.

2. MAPS scale (multidimensional assessment pain scale) (Table 4). This scale is based on the observation of body movements and facial expression. It is a multidimensional scale that also includes physiological parameters, such as breathing, changes in blood pressure (BP) and heart rate (HR). Similar to the FLACC scale, it classifies pain on a scale from 0 (no pain) to 9–10 (unbearable pain) [59].

| Vital signs: HR and/or BP | 0 | 1 | 2 |
|--------------------------|---|---|---|
| Vital signs: HR and/or BP | Within baseline | More than 10 bpm increase and/or more than 10 mmHg increase | More than 10 bpm decrease and/or more than 10 mmHg decrease |
| Breathing pattern        | No change | Development or increase in respiratory distress | Severe respiratory distress |
| Facial expression        | Relaxed | Grimace | Grimace associated with silent or weak cry |
| Body movements           | No movements or purposeful movements | Restless | Rigid and/or limited body movements |
| State of arousal         | Calm or asleep | Hyperreactive | Shut down |

No pain, 0; mild pain, 1–2; moderate pain, 3–5; severe pain, 6–8; extreme–maximum pain, 9–10.
5.3.2. Objective Pain Monitoring

Some monitors detect physiological changes that occur in association with painful stimuli and stress based on electromyograms, plethysmography, electrocardiograms, skin conductance or measurement of the diameter of the pupil. Such monitors can quantify the intensity of pain and the response to treatment. These parameters are objective, non-invasive, relatively easy to use and can be used at the patient’s bedside. However, they are unspecific (other non-pain stimulus, such as agitation, fear and stress, produce the same response) and are expensive. Therefore, they have not yet been applied in clinical settings [60,61]. Such monitors include:

Conductance skin impedance monitor (Medstorm Innovations, Oslo, Norway), which assesses the stress response through changes in skin conductance produced by sympathetic stimulation. It is non-invasive with rapid response but does not differentiate between agitation and pain and it is not able to measure baseline stress [62].

The analgesia nociception index (ANI), which is based on the RR variability of ECG intervals. This is a continuous line measurement of parasympathetic tone, which is part of the autonomic nervous system that assesses nociception [63,64].

The pain pupillary index (PPI) measurement, which provides real-time information from a video camera and infrared pupillary diameter [65].

6. Treatment

In the 2010 Montreal Declaration, access to pain treatment was declared a fundamental human right, constituting a violation of human rights not to treat pain [66–71].

It is important to develop treatment protocols to prevent procedural pain by combining pharmacological and non-pharmacological strategies. The intensity of analgesia should be adjusted to the intensity of the potential pain and ensure adequate supervision and monitoring [72,73].

6.1. Non-Pharmacological Analgesia

The aim of non-pharmacological analgesia is to increase patient comfort and reduce stress related to diagnostic or therapeutic procedures [74,75]. It should not be used as a substitute for pharmacological treatment but should be combined with pharmacological treatment [76–78].

Mechanisms of action are not yet well explained, but such interventions likely reduce the sensitivity of the nociceptive system. Some such measures release endogenous endorphins, activating opioid-enhancing neuropeptides inducing distraction from pain.

Such measures can be classified based on the mechanism of action [79].

Environmental strategies: low noise and lighting, soothing smells or clustering procedures to avoid over handling by modifying the environment to reduce sensibility to pain.

Cognitive strategies, including distraction methods, particularly used in older children.

Behavioral strategies, including direct (rocking) or indirect (non-nutritive sucking) manipulation of the infant’s body. These techniques produce relaxing tactile stimuli before, during and/or after the painful procedure to reduce pain [80,81].

The main non-pharmacological strategies used in neonates and children are:

Posture and mobilization: Mobilizations are applied using pillows or devices to help increase well-being [79]. This strategy is effective in term and preterm babies.

Breastfeeding or expressed breast milk: breastfeeding [82] is one of the most effective non-pharmacological strategies. Supplemental breast milk is less effective than breastfeeding and sucrose [83,84].

Oral sucrose and glucose [85]: It remains unclear whether sucrose suppresses the responses to pain. It should be administered 2 min before the procedure, and the effect lasts approximately 4 min [86].

Non-nutritive sucking [79], which can be achieved with a pacifier, breastfeeding after extraction or with the finger. It is effective in term and preterm babies.

Skin-to-skin contact (kangaroo care) [87], which is effective for pain relief in neonates.
Sensorial saturation [88], which results from multimodal sensory inputs (e.g., touch, massage, taste, voice and smell) during a painful procedure.

Distraction: attracting attention, keeping thoughts occupied and away from pain (music, images, games, etc.) [89].

Cognitive reformulation: in older children, recognize thoughts that increase pain and replace them with positive thoughts.

Music therapy [90]: it can improve heart rate, feeding and sucking in preterm infants.

Mother’s voice: some studies have demonstrated analgesic qualities in neonates that resulting from exposure to the mother’s voice [91].

Other measures studied for the relief pain include massage therapy [92], medical acupuncture [93,94], osteopathic manipulation [95] and radiant warming [96] or localized warming for painful procedures.

The main advantages of non-pharmacological treatments include ease of learning and performance, as well as safety and feasibility. However, no studies have been conducted to date analyzing the long-term effects of these techniques [81].

6.2. Pharmacological Analgesia

6.2.1. Concepts

The responsible physician must establish the treatment, depending on the age, type and intensity of the pain (Figures 1 and 2), as well as the underlying disease, and assess the following aspects:

- Patient’s age and associated pathology (cardiorespiratory, renal and hepatic function);
- Check for interactions of analgesics with other medications the patient is receiving; and
- Prevent and treat the most common side effects of analgesics [97].

![Figure 1. Algorithm for pain assessment and management in neonates.](image-url)
Figure 1. Algorithm for pain assessment and management in neonates.

Figure 2. The analgesic ladder proposed by the World Health Organization (WHO) for children [96].

An analgesic regimen and analgesic rescue should be prescribed according to the intensity of pain [98] (Figure 2). Pharmacotherapeutic protocols for pediatric pain need to be established according to intensity, age and the form of drug administration [99–102].

6.2.2. Pharmacological Analgesia in Neonates

The most used pharmacological analgesia in neonates are paracetamol, opioids and local anesthetics [44,103]. The doses and effects of most frequent drugs used in neonates are summarized in Table 5 [104–112].

Table 5. Pharmacological agents for neonatal pain management.

| Drug   | Dose                                      | Pharmacology               | Indications                                                                 | Adverse Effects                                                                 |
|--------|-------------------------------------------|----------------------------|----------------------------------------------------------------------------|--------------------------------------------------------------------------------|
| Morphine | Boluses: 30–50 mcg/kg, maximum 100 mcg/kg over 15–30 min | Action of 5 min. Peak effectiveness: 15 min. Half-life: 6–12 h | Analgesia and sedation in mechanical ventilation; postoperative pain control; sedation during therapeutic hypothermia. | Hypotension, respiratory arrest, urinary retention, tolerance, withdrawal, risk of periventricular leukomalacia and/or death; poor long-term neurodevelopmental outcomes |
|        | Infusion: 30–100 mcg/kg bolus followed by 10 mcg/kg/h |                            |                                                                            |                                                                                 |
|        | A lower initial dose is recommended. Therapeutic hypothermia: Bolus of 50 mcg/kg, followed by 5 mcg/kg/h infusion |                            |                                                                            |                                                                                 |
| Fentanyl| Bolus of 0.5–2.0 µg/kg Infusion: 0.5–2.0 µg/kg/h | Action of 1–2 min. Duration of action: 60 min. Half-life: 3.1–9.5 h | Analgesia and sedation in mechanical ventilation; sedation during therapeutic hypothermia | Respiratory arrest, chest wall rigidity, laryngospasm, tolerance withdrawal, delayed meconium passage. Cerebellar hypoplasia; decrease in eye and hand coordination skills at two years |
|        | Preterm neonates born before 32 w g reduced by 50% during days 0–4, Therapeutic hypothermia 1–2 mcg/kg over one hour and then infusion to 0.5–1 mcg/kg/h |                            |                                                                            |                                                                                 |
### Table 5. Cont.

| Drug         | Dose                                      | Pharmacology                        | Indications                                                                 | Adverse Effects                                                                 |
|--------------|-------------------------------------------|-------------------------------------|------------------------------------------------------------------------------|--------------------------------------------------------------------------------|
| Remifentanil | Endotracheal intubation: 1–2 µg/kg.       | Action: 1 min                       | Short procedures: endotracheal intubation, laser surgery for retinopathy of prematurity | Bradycardia, hypotension, chest wall rigidity, tolerance and withdrawal; no studies of long-term outcome in neonates |
|              | Percutaneous central venous catheter: 0.25 µg/kg/min | Half-life: 3.5–5 min.                |                                                                               |                                                                                 |
|              | Sedation and analgesia in mechanical ventilation: 0.15 µg/kg/min | |                                                                               |                                                                                 |
| Paracetamol  | Oral dose: 25 mg/kg/day in at 30 w, 45 mg/kg/day at 34 w, 60 mg/kg/day in term | IV action: 5 min. Peak effectiveness: 15 min | Mild to moderate pain; reduction in morphine requirements after major surgery | Hardly causes hepatic or renal toxicity in newborns; minor hemodynamic effects have been found following IV; Following neonatal exposure to paracetamol remains limited; possible link with risks for atopy, fertility and neurobehavioral problems |
|              | Intravenous: 20 mg/kg loading dose, followed by a 10 mg/kg maintenance dose every six hours. 28 to 31 wg, to 12 h | Oral peak effectiveness: 1 h |                                                                               |                                                                                 |
|              | Enteral and rectal; variable absorption | |                                                                               |                                                                                 |
| Dexmedetomidine | Bolus 0.05–0.2 mg/kg over 15 min followed by maintenance 0.47 ± 0.21 mg/kg/h | Half-life: 7.6 h preterm and 3.2 h in term infants | Alternative agent for sedation in mechanical ventilation. Sedation of term neonates during therapeutic hypothermia; no studies in neonates | Hypotension and bradycardia generally self-limiting; reduced dosed withdrawal (weaned by decreasing the infusion by 0.1 mcg/kg/h every 12 to 24 h) |
|              | Therapeutic hypothermia 0.3 mcg/kg/h (range 0.2–0.5 mcg/kg/h) | |                                                                               |                                                                                 |
| Ketamine     | Bolus 1–2 mg/kg                          | Action: 1–2 min; short duration: 15–30 min | Short painful procedures; hemodynamically unstable patients; no studies in neonates | Possible Neurotoxicity; no studies of long-term outcome in neonates |

Pharmacological pain management also involves risks of adverse effects, such as respiratory depression or neurotoxicity. This association is particularly evident for prolonged or repeated exposure to analgosedative drugs [38,104].

Opioids should not be administered routinely in neonates with mechanical ventilation, owing to the possible neurotoxicity of opioids in the developing brain [38,104–106]. Opioid administration should be based on clinical evaluation and scales [107]. The use of combined analgesic regimens permits a reduction in the dose of opioids by maintaining adequate analgesia with reduced frequency of side effects [107,108].

Current guidelines promote a pharmacological therapy administered in a stepwise approach, together with regular assessment of pain and sedation scores [53,109–112].

### 6.2.3. Pharmacological Analgesia in Children

A variety of analgesic drugs is available [113–119]. Table 6 summarizes the drugs, doses and effects of the most commonly used analgesics in pediatrics [98–101,108,113–122]. Pharmacological analgesia in children depends on the procedure, kind and intensity of pain and the age of the patient (Table 7) [120–122].
| Drug            | Dose                                                                 | Indications                  | Comments and Main Side Effects                  |
|-----------------|----------------------------------------------------------------------|------------------------------|------------------------------------------------|
| Acetaminophen   | po/pr: 5–10 mg/kg/h IV: 10–15 mg/kg/6 h (<10 kg: 7.5 mg/kg/6 h)      | Moderate pain Hyperthermia   | - Hepatotoxicity                               |
|                 | <1 year: 7.5 mg/kg                                                   |                              |                                                |
| Ibuprofen       | po: 5–10 mg/kg/6 h IV: 5–10 mg/kg/6 h                                | Moderate pain Hyperthermia   | - Of choice in children                        |
|                 |                                                                      |                              | - Gastrointestinal bleeding                    |
| Metamizole      | po: 10–15 mg/kg/6–8 h IV: 10–20 mg/kg/6–8 h                           | Moderate–severe pain Hyperthermia | - Synergistic effect with opioids               |
|                 |                                                                      |                              | - Bone marrow aplasia                          |
| Dexketoprofen   | po: 0.5–1 mg/kg/8 h IV/im: 10–40 mg/kg/8 h                           | Moderate–severe pain Anti-inflammatory | - Not recommended for children under 12 years of age |
|                 |                                                                      |                              | - Gastrointestinal bleeding                    |
| Ketorolac       | po: 0.5 mg/kg/6–8 h IV: 0.2–1 mg/kg/6–8 h                             | Moderate–severe pain Anti-inflammatory | - Gastrointestinal bleeding                   |
|                 |                                                                      |                              | - Nephrotoxicity                               |
| Naproxen        | po/pr/im: 5 mg/kg/8–12 h                                             | Mild–moderate pain Anti-inflammatory | - Not recommended for children under 12 years of age |
|                 |                                                                      |                              | - No IV                                        |
|                 |                                                                      |                              | - Gastrointestinal bleeding                    |
| Diclofenac      | po: 0.5–1.5 mg/kg/8 h                                                | Mild–moderate pain Spasmolytic | - Spasmodic effect                             |
|                 |                                                                      |                              | - Gastrointestinal bleeding                    |
| Tramadol        | po/pr/sc: 1–2 mg/kg/4–6 h iv: 1–2 mg/kg/4–6 h                         | Acute pain                   | - Good hemodynamic tolerability                |
|                 |                                                                      |                              | - Less respiratory effect                      |
| Meperidine      | IV/im/sc: 0.5–2 mg/kg/4–6 h                                          | Acute pain Spasmolytic       | - Constipation                                 |
|                 |                                                                      |                              | - Urinary retention                            |
| Morphine        | po: 0.2–0.5 mg/kg/6–8 h IV/im/sc: 0.1–0.2 mg/kg/4–6 h CII: 10–50 mcg/kg/h | Analgesedation in conventional mechanical ventilation Acute or chronic pain Pulmonary edema | - Dose adjustment in renal and hepatic failure - Release of histamine, nausea, vomiting and respiratory arrest |
| Fentanyl        | IV/sc/sl/in: 1–3 mcg/kg CII: 1–10 mcg/kg/h                            | Procedural pain Analgesedation in conventional mechanical ventilation Acute or chronic pain Pulmonary edema | - Long elimination - Improved cardiocirculatory stability - Chest stiffness and respiratory arrest |
### Table 6. Cont.

| Drug              | Dose                          | Indications                     | Comments and Main Side Effects                          |
|-------------------|-------------------------------|---------------------------------|--------------------------------------------------------|
| Nitrous oxide     | 20–70% with oxygen           | Procedural pain                 | Nausea, vomiting                                       |
|                   |                               | Endoscopy and venipunctures     | Myocardial dysfunction Neurodevelopment effects?       |

- po: per os; pr: per rectal; in: intranasal; sl: sublingual; sc: subcutaneous; IV: intravenous infusion; CII: continuous intravenous infusion.

### Table 7. Pain treatment according to intensity and patient age.

| Age         | Mild Pain                  | Moderate Pain                   | Severe Pain                           |
|-------------|----------------------------|---------------------------------|---------------------------------------|
| <1 year old | Adequate oral tolerance   |                                 |                                        |
|             | - Ibuprofen 2%: 4–10 mg/kg/oral 8 h |                                 |                                        |
|             | - Rescue                   |                                 |                                        |
|             | (a) Acetaminophen 100 mg/mL: 10 mg/kg/6–8 h/oral |             |                                        |
|             | (b) Metamizole: 12.5 mg/kg/8 h (max 500 mg/dose) |             |                                        |
| No oral tolerance | Acetaminophen IV: 7.5–10 mg/kg/6–8 h |             |                                        |
|             | - Rescue                   |                                 |                                        |
|             | Metamizole: 20 mg/kg/IV/8 h  |                                 |                                        |
| >1 year old | Adequate oral tolerance   |                                 |                                        |
|             | - Ibuprofen 2%: 4–10 mg/kg/oral 8 h |                                 |                                        |
|             | - Rescue                   |                                 |                                        |
|             | (a) Acetaminophen 100 mg/mL: 10 mg/kg/6–8 h/oral |             |                                        |
|             | (b) Metamizole: 12.5 mg/kg/8 h (max 500 mg/dose) |             |                                        |
| No oral tolerance | Acetaminophen IV: 10–15 mg/kg/6–8 h |             |                                        |
|             | - Rescue                   |                                 |                                        |
|             | Metamizol IV 20 mg/kg/8 h   |                                 |                                        |

| Age         | Adequate oral tolerance   |                                 |                                        |
|-------------|----------------------------|---------------------------------|---------------------------------------|
| <1 year old |                                |                                 | Intronavens                            |
|             | - Ibuprofen 2%: 4–10 mg/kg/oral 8 h | 7.5–10 mg/kg/IV/6–8 h + |
|             | - Rescue                   | Acetaminophen 100 mg/mL: 10 mg/kg/6–8 h/oral | Metamizole: 20 mg/kg/8 h (max 500 mg/dose) |
|             | (a) Acetaminophen 100 mg/mL: 10 mg/kg/6–8 h/oral | | |
|             | (b) Metamizole: 12.5 mg/kg/8 h (max 500 mg/dose) | | |
| No oral tolerance | Acetaminophen IV: 20 mg/kg/IV/8 h | | Continuous respiratory rate and oximetry monitoring |
|             | - Rescue                   |                                 |                                        |
|             | Metamizole: 20 mg/kg/8 h    |                                 |                                        |

| Age         | Adequate oral tolerance   |                                 |                                        |
|-------------|----------------------------|---------------------------------|---------------------------------------|
| >1 year old |                                |                                 | Intronavens                            |
|             | - Ibuprofen 2%: 4–10 mg/kg/oral 8 h | 10–15 mg/kg/6–8 h + |
|             | - Rescue                   | Acetaminophen IV: 20–40 mg/kg/8 h | Metamizole 120 mg/kg/IV/CII in 24 h  |
|             | (a) Metamizole: 20 mg/kg/8 h (max 500 mg/dose) | | + morphine: 0.1–0.25 mg/kg/IV/6 h |
|             | (b) Tramadol 1 mg/kg/6 h (max 8 mg/kg/24 h) | | |
| No oral tolerance | Acetaminophen IV: 10–15 mg/kg/6–8 h | | Continuous respiratory rate and pulse oximetric monitoring |
|             | - Rescue                   |                                 |                                        |
|             | Morphine 0.1–0.25 mg/kg/IV/6 h | |                                        |
|             | Pethidine 0.5 mg/kg/IV/6 h   | |                                        |
6.3. Local Analgesia

Multiple formulations of topical anesthetics are available for use in children. The most used are included in Table 8 [123–127].

Table 8. Local analgesia in newborns and children.

| Drug Dose | Indications | Adverse Effects |
|-----------|-------------|-----------------|
| **EMLA (lidocaine 2.5%-prilocaine 2.5%).** 0.5 g to 1.0 g applied to the procedural site; anesthesia within 60–90 min | Lumbar puncture, venipuncture, circumcision | Methemoglobinemia |
| **Tetracaine gel.** Applied to the procedural site | Intramuscular injection and heel sticks | Transient local erythema |
| **Liposomal lidocaine 4% cream (LMX4)** Applied to the procedural site; anesthesia within 30 min | Venipuncture, skin biopsies, lesion removal and electrocautery | No risk of methemoglobinemia |
| **Lidocaine** Subcutaneous infiltration; 0.5 mL/kg of 1% or 0.25 mL/kg of 2% | Lumbar puncture, circumcision, percutaneous venous or arterial catheter placement | In neonates, avoid combination with epinephrine (risk of tissue necrosis and tachyarrhythmias) |
| **Proparacaine anesthetic eye drops (alcaine) 0.5%** 30 s before eye examination | Retinopathy of prematurity screening | Eye redness |

6.4. Other Methods

Patients with severe pain that is not well controlled despite powerful opioids at full dosages can become candidates for special anesthesia and regional analgesia techniques [94]. Patients with high tolerance to opioids, severe adverse effects, chest pain with respiratory compromise or chronic pain may also be candidates for these techniques.

6.4.1. PCA Pumps

From the age of 6–7 years, well-educated children with adequate cognitive abilities are able to self-administer analgesics by means of a PCA-programmed device [128]. The most commonly used modality in pediatrics is the mixed mode, whereby the pump administers a minimal basal continuous infusion, and if this is not sufficient, the patient can self-administer boluses until pain is eliminated or reduced. The system has important psychological advantages, especially for adolescents, by improving the perception of control over their own pain and reducing unnecessary analgesic consumption and side effects of opioid drugs. The most commonly used opioids in pediatrics are morphine, fentanyl, hydromorphone, oxycodone and tramadol. In pediatric patients under 6 years of age or without adequate cognitive capacity, the “PCA by proxy” modality can be used, whereby the nurse administers the analgesic rescue boluses (“nurse PCA”) or even selected parents (“parent PCA”).

6.4.2. Regional and Interventional Analgesia Techniques

Regional techniques have been applied in children with satisfactory results [129–131]. The most common technique is epidural analgesia, which can be given at any level of the neuroaxis and which, by insertion of a catheter, allows analgesia to be maintained for several days or even weeks if necessary. In such cases, the catheter must be tunneled. Other catheter-based analgesia techniques, such as paravertebral, fascial and incisional analgesia use, have increased in popularity in pediatric patients [128] (Table 9). In all such techniques, local anesthetics are administered alone or in combination with adjuvants, such
as opioids, clonidine, dexmedetomidine or corticosteroids, which enhance their duration and effect. Regional and invasive techniques provide pain elimination without causing CNS side effects, such as those produced by opioids.

Table 9. Interventional techniques for pediatric pain.

| Technique                | Pediatric Experience | Indications                                                                 | Guided                        |
|-------------------------|----------------------|------------------------------------------------------------------------------|-------------------------------|
| Neuroaxial block        | Very extensive       | Oncological pain, neuropathic pain, complex regional pain, refractive phantom limb | Loss of resistance US, Radioscopy |
| Peripheral nerve block  | Extensive            | Oncological pain, neuropathic pain, complex regional pain, refractive phantom limb | US Electric stimulation       |
| Sympathetic block       | Less extensive       | Complex regional pain, herpes, visceral pain                                 | US, Radioscopy                |
| Major occipital nerve   | Less extensive       | Occipital neuralgia, post-traumatic headache, migraine                       | US                            |
| Fascial blocks:         | Less extensive       | Abdominal wall pain, Post herniorrhaphy neuralgia Cutaneous nerve entrapment syndrome Myofascial pain | US                            |
| TPA (transversal plane abdomen), rectus fascia, iliac fascia, and ilioinguinal fascia | | | |
| IV block (Bier)         | Less extensive       | Neuropathic pain, complex regional pain                                       | US                            |
| Chemical neurolysis     | Short experience     | Oncological pain, spasticity                                                  | Radioscopy, US                |
| Radiofrequency          | Short experience     | Refractory neuropathic pain, joint pain, oncological pain                     |                               |
| Transcutaneous electrical nerve stimulation (TENS); spinal cord, brain | Very extensive Less extensive; very short experience | Neuropathic pain, complex regional pain                                         | Radioscopy, US Radioscopy + surgery |
| Intrathecal baclofen    | Extensive            | Infantile spastic cerebral palsy, dystonia                                   | Radioscopy, US                |
| Intra-articular         | Extensive            | Juvenile idiopathic rheumatoid arthritis, spondylitis                        | US                            |

CAT: US: Ultrasound.

7. Pain Assessment and Treatment Algorithm

The objective of the evaluation of pain and stress is to detect pain and determine the appropriate analgesic dose for each patient without side effects of treatment.

The first step to individualize the treatment of each patient is to implement a validated pain assessment tool, usually clinical scales (the fifth vital sign).

The second step is to evaluate other indicators of the patient, environment and therapies. To establish the treatment of pain, the assessment of pain, the environment, the individual characteristics of the patient, the underlying disease and other treatments must be taken into account.

It is not helpful to implement pain assessment as a stand-alone procedure. Therefore, pain assessment must be followed by a stepped treatment protocol adapted to the patient, as well as a structured follow-up and with multidisciplinary responsibility.
It is recommended to perform multimodal analgesia with non-pharmacological and/or pharmacological interventions. Subsequently, the patient must be re-evaluated to check the response and adjust the medications at the lowest dose necessary at each moment.

Figures 1 and 2 summarize the algorithm for the assessment and treatment of pain in neonates and children.

8. Conclusions

Pain assessment is complicated, especially in neonates, infants and preschool-aged children. We recommend using clinical scales adapted to the age of the patient to assess and monitor the degree of pain in children.

We recommend multimodal analgesia with non-pharmacological and pharmacological interventions for pain treatment and the establishment of pharmacotherapeutic protocols for analgesia adjusted to the acute or chronic, type and intensity of pain, as well as the age of the patient. Patient-controlled analgesia is an adequate alternative for adolescents and older children in specific situations, such as after surgery. Patients with severe or persistent pain should be treated in consultation with specific pain services.

The follow-up of structured protocols will enable early diagnosis of pain and treatment adapted to the intensity and characteristics of the pain and of the child, which can reduce suffering and contribute improved prognosis.

Author Contributions: All authors contributed to the conceptualization and writing. All authors have read and agreed to the published version of the manuscript.

Funding: This research was supported by RETICS “Maternal and Child Health and Development Network II (SAMID II), funded by the PN I+D+i 2013–2016 (Spain), ISCIII-Sub-Directorate General for Research Assessment and Promotion and the European Regional Development Fund (ERDF), ref. RD16/0022.

Acknowledgments: Maternal and Child Health and Development Network II (SAMID II)

Fetal authors
- Garcia-Algar O, Neonatology Unit, ICGON, Hospital Clinic-Maternitat, BCNatal, Barcelona, Spain;
- Andreu-Fernandez V, Grup de Recerca Infancia i Entorn (GRIE), Institut d’investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Madrid, Spain; Valencian International University (VIU), Valencia, Spain
- Gomez-Roig MD, Institut de Recerca Sant Joan de Déu, Esplugues de Llobregat, Spain; BCNatal, Barcelona, Spain
- Almeida L, Institut de Recerca Sant Joan de Déu, Esplugues de Llobregat, Spain; BCNatal, Barcelona, Spain.

Neonatal authors
- Gerardo Rodriguez Growth, Exercise, Nutrition and Development (GENUD) Research Group, Universidad de Zaragoza, Spain. Instituto de Investigación Sanitaria Aragón (IIS Aragón), Spain
- Iris Iglesia. Growth, Exercise, Nutrition and Development (GENUD) Research Group, Universidad de Zaragoza, Spain. Instituto de Investigación Sanitaria Aragón (IIS Aragón), Spain
- Maria Cruz López Herrera. Department of Neonatology. Cruces University Hospital. Baracaldo (Vizcaya, Spain).
- Margarita Ferrer. Department of Neonatology. Cruces University Hospital. Baracaldo (Vizcaya, Spain).
- Fernando Cabañas Department of Paediatrics and Neonatology. Quironsalud Madrid University Hospital. Madrid
- Manuela Lopez-Azorin. Department of Paediatrics and Neonatology. Quironsalud Madrid University Hospital. Madrid
- Carmen Pallas Alonso Department of Neonatology. 12 de Octubre University Hospital. Madrid.
- Clara Alonso. Department of Neonatology. 12 de Octubre University Hospital. Madrid.
Children 2022, 9, 1688

Pediatric authors

- Santiago Mencia. Pediatric Intensive Care Department. Hospital General Universitario Gregorio Marañón de Madrid.
- Jesús López-Herce. Pediatric Intensive Care Department. Hospital General Universitario Gregorio Marañón de Madrid.
- Raquel Cieza. Pediatric Intensive Care Department. Hospital General Universitario Gregorio Marañón de Madrid.
- Jesús Cebrián. Sección de anestesia Pediátrica. Hospital General Universitario Gregorio Marañón de Madrid.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Treede, R.D. The International Association for the Study of Pain definition of pain: As valid in 2018 as in 1979, but in need of regularly updated footnotes. Pain Rep. 2018, 3, e643. [CrossRef]
2. Bondesson, E.; Olofsson, T.; Caverius, U.; Schelin, M.E.C.; Jöud, A. Consultation prevalence among children, adolescents and young adults with pain conditions: A description of age- and gender differences. Eur. J. Pain 2020, 24, 649–658. [CrossRef] [PubMed]
3. Curtis, S.; Winger, A.; Ali, S. The Cochrane Library and procedural Pain in children: An overview of reviews. Evid. Based Child Health 2012, 7, 1363–1399. [CrossRef]
4. Shah, P.; Siu, A. Considerations for neonatal and pediatric pain management. Am. J. Health Syst. Pharm. 2019, 76, 1511–1520. [CrossRef] [PubMed]
5. Peng, P.; Stinson, J.N.; Choiniere, M.; Dion, D.; Intrater, H.; Lefort, S.; Tkachuk, G.; et al. Dedicated multidisciplinary pain management centres for children in Canada. Can. J. Anesth. 2007, 54, 985–991. [CrossRef] [PubMed]
6. Stevens, B.J.; Yamada, J.; Estabrooks, C.A.; Stinson, J.; Campbell, F.; Scott, S.D.; Cummings, G.; CIHR Team in Children’s Pain. Pain in hospitalized children: Effect of a multidimensional knowledge translation strategy on pain process and clinical outcomes. PAIN 2014, 155, 60–68. [CrossRef]
7. Anand, K.J.; Hickey, P.R. Pain and its effects in the human neonate and fetus. N. Engl. J. Med. 1987, 317, 1321–1329. [CrossRef]
8. Derbyshire, S.W. Foetal pain? Best Pract. Res. Clin. Obstet. Gynaecol. 2010, 24, 647–655. [CrossRef]
9. Anand, K.J.; Carr, D.B. The neuroanatomy, neurophysiology, and neurochemistry of pain, stress, and analgesia in newborns and children. Pediatr. Clin. N. Am. 1989, 36, 795–822. [CrossRef]
10. Lee, S.J.; Ralston, H.J.P.; Drey, E.A.; Partridge, J.C.; Rosen, M.A. Fetal pain: A systematic multidisciplinary review of the evidence. JAMA 2005, 294, 947–954. [CrossRef] [PubMed]
11. Lowery, C.L.; Hardman, M.P.; Manning, N.; Hall, R.W.; Anand, K.J.; Clancy, B. Neurodevelopmental changes of fetal pain. Semin. Perinatol. 2007, 31, 275–282. [CrossRef] [PubMed]
12. Kanold, P.O.; Luhmann, H.J. The Subplate and Early Cortical Circuits. Annu. Rev. Neurosci. 2010, 33, 23–48. [CrossRef] [PubMed]
13. Sekulic, S.; Gebauer-Bukurov, K.; Cvijanovic, M.; Kopitovic, A.; Ilic, D.; Petrovic, D.; Capo, I.; Pericin-Starcevic, I.; Christ, O.; Topalidou, A. Appearance of fetal pain could be associated with maturation of the mesodiencephalic structures. J. Pain Res. 2016, 9, 1031–1038. [CrossRef] [PubMed]
14. Bouza, H. The impact of pain in the immature brain. J. Matern. Fetal Neonatal Med. 2009, 22, 722–732. [CrossRef]
15. Bellieni, C.V. New insights into fetal pain. Semin. Fetal Neonatal Med. 2019, 24, 101001. [CrossRef]
16. Reissland, N.; Francis, B.; Mason, J. Can healthy fetuses show facial expressions of “pain” or “distress”? Plots ONE 2013, 8, e65530. [CrossRef]
17. Jardri, R.; Pins, D.; Houfllin-Debargue, V.; Chaffiotte, C.; Rocourt, N.; Pruvost, J.P.; Steinling, M.; Delion, P.; Thomas, P. Fetal cortical activation to sound at 33 weeks of gestation: A functional MRI study. Neuroimage 2008, 42, 10–18. [CrossRef]
18. Matusz, T.; Govindan, R.B.; Preissl, H.; Siegel, E.R.; Muenssinger, J.; Murphy, P.; Ware, M.; Lowery, C.L.; Eswaran, H. Habituation of visual evoked responses in neonates and fetuses: A MEG study. Dev. Cogn. Neurosci. 2012, 2, 303–316. [CrossRef]
19. Bellieni, C.V.; Sisto, R.; Cordelli, D.M.; Buonocore, G. Cry features reflect pain intensity in term newborns: An alarm threshold. Pediatr. Res. 2004, 55, 142–146. [CrossRef]
20. Gingras, J.L.; Mitchell, E.A.; Grantan, K.E. Fetal homologue of infant crying. Arch. Dis. Child Fetal Neonatal Ed. 2005, 90, F415–F418. [CrossRef]
21. Bernardes, L.S.; Ottolia, J.F.; Cecchini, M.; de Amorim Filho, A.G.; Teixeira, M.J.; Francisco, R.P.V.; de Andrade, D.C.; Grupo de Estudo da Dor Fetal (Fetal Pain Study Group). On the feasibility of accessing acute pain–related facial expressions in the human fetus and its potential implications: A case report. Pain Rep. 2018, 3, e673. [CrossRef] [PubMed]
22. Petrikovsky, B.M.; Kaplan, G.P. Fetal responses to inadvertent contact with the needle during amniocentesis. Fetal Diagn. Ther. 1995, 10, 83–85. [CrossRef] [PubMed]
23. Giannakoulopoulos, X.; Glover, V.; Sepulveda, W.; Kourtis, P.; Fisk, N.M. Fetal plasma cortisol and β-endorphin response to intrauterine Needling. Lancet 1994, 344, 77–81. [CrossRef]
24. Schuller, C.; Känel, N.; Müller, O.; Kind, A.B.; Tinner, E.M.; Hösl, I.; Zimmermann, R.; Surbek, D. Stress and pain response of neonates after spontaneous birth and vacuum-assisted and cesarean delivery. *Am. J. Obstet. Gynecol.* 2012, 207, e1–e6. [CrossRef]

25. Duci, M.; Pulvirenti, R.; Fascetti Leon, F.; Capoluipo, I.; Veronese, P.; Gamba, P.; Tognon, C. Anesthesia for fetal operative procedures: A systematic review. *Front. Pain Res.* 2022, 3, 935427. [CrossRef]

26. Braden, A.; Maani, C.; Nagy, C. Anesthetic management of an ex utero intrapartum treatment procedure: A novel balanced approach. *J. Clin. Anesth.* 2016, 31, 60–63. [CrossRef]

27. Kornacki, J.; Szydlowski, J.; Skrzypeczak, J.; Szczepańska, M.; Rajewski, M.; Koziolek, A.; Gaca, M.; Wender-Ożegowska, E. Use of ex utero intrapartum treatment procedure in fetal neck and high airway anomalies—report of four clinical cases. *J. Matern. Fetal Neonatal Med.* 2019, 32, 870–874. [CrossRef]

28. Han, G.; Li, L.; Tian, Y.; Xue, H.; Zhao, P. Influences of different doses of midazolam on mother and fetus in fetoscopic surgery for twin-to-twin transfusion syndrome. *Pharmacology* 2015, 96, 151–154. [CrossRef]

29. Ruano, R.; Yoshisaki, C.; Da Silva, M.; Ceccon, M.; Grasi, M.; Tannuri, U.; Zugaib, M. A randomized controlled trial of fetal endoscopic tracheal occlusion versus postnatal management of severe isolated congenital diaphragmatic hernia. *Ultrasound Obstet. Gynecol.* 2012, 39, 20–27. [CrossRef] [PubMed]

30. Chmait, R.H.; Chon, A.H.; Anselmo, D.; Vanderbilt, D.L.; Townsend, J.; Julian-Wang, B.; Don, D. In utero fetal intubation for a large neck mass: A minimally invasive EXIT option. *Fetal Diagn. Ther.* 2014, 29, 275–280. [CrossRef]

31. Pedreira, D.A.; Zanon, N.; Nishikuni, K.; de Sá, R.A.M.; Acacio, G.L.; Chmait, R.H.; Kontopoulos, E.V.; Quintero, R.A. Endoscopic surgery for the antenatal treatment of myelomeningocele: The CECAM trial. *Am. J. Obstet. Gynecol.* 2016, 214, e1–e111. [CrossRef] [PubMed]

32. Digiusto, C.; Winer, N.; Benoist, G.; Laurichesse-Delmas, H.; Potin, J.; Binet, A.; Morel, B.; Perrotin, F. In-utero aspiration vs expectant management of anechoic fetal ovarian cysts: Open randomized controlled trial. *Ultrasound Obstet. Gynecol.* 2018, 52, 159–164. [CrossRef] [PubMed]

33. Said, S.M.; Qureshi, M.Y.; Taggart, N.W.; Anderson, H.N.; O'Leary, P.W.; Cetta, F.; Alrahmani, L.; Cofer, S.A.; Segura, L.G.; Pike, R.B.; et al. Innovative 2-step management strategy utilizing EXIT procedure for a fetus with hypoplastic left heart syndrome and intact atrial septum. *Mayo Clin. Proc.* 2019, 94, 356–361. [CrossRef] [PubMed]

34. Tkaczyk, M.; Stanczyk, M.; Krzeszowski, W.; Wojtera, J.; Litwinska, M.; Fortecka-Piestrzeniewicz, K.; Talar, T.; Pawlowska, B.; Olejniczak, D.; Podgórski, M.; et al. Neonatal survival and kidney function after prenatal interventions for obstructive uropathies. *Ginekol. Pol.* 2019, 90, 416–422. [CrossRef]

35. Baud, D.; Windrim, R.; Kachura, J.; Jefferies, A.; Pantazi, S.; Shah, P.; Langer, J.C.; Forsey, J.; Chaturvedi, R.R.; Jaeggi, E.; et al. Minimally invasive fetal therapy for hydropic lung masses: Three different approaches and review of the literature. *Ultrasound Obstet. Gynecol.* 2013, 42, 440–448. [CrossRef]

36. Goksan, S.; Hartley, C.; Emery, F.; Cockrill, N.; Poorun, R.; Moultrie, F.; Rogers, R.; Campbell, J.; Sanders, M.; Adams, E.; et al. fMRI reveals neural activity overlap between adult and infant pain. *Elife* 2015, 4, e08663.2. [CrossRef]

37. McPherson, C.; Miller, S.P.; El-Dib, M.; Massaro, A.N.; Inder, T.E. The influence of pain, agitation, and their management on the immature brain. *Pediatr. Res.* 2020, 88, 168–175. [CrossRef]

38. Doesburg, S.M.; Chau, C.M.; Cheung, T.P.; Moiseev, A.; Ribary, U.; Herdman, A.T.; Miller, S.P.; Cepeda, I.L.; Synnes, A.; Grunau, R.E. Neonatal pain-related stress, functional cortical activity and visual-perceptual abilities in school-age children born at extremely low gestational age. *Pain* 2013, 154, 1946–1952. [CrossRef]

39. Ranger, M.; Chau, C.M.; Garg, A.; Woodward, T.S.; Berg, M.F.; Bjornson, B.; Poskitt, K.; Fitzpatrick, K.; Synnes, A.R.; Miller, S.P.; et al. Neonatal pain-related stress predicts cortical thickness at age 7 years in children born very preterm. *PLoS ONE* 2013, 8, e76702. [CrossRef]

40. Moultrie, F.; Slater, R.; Hartley, C. Improving the treatment of infant pain. *Curr. Opin. Support Palliat. Care* 2017, 11, 112–117. [CrossRef]

41. Tortora, D.; Severino, M.; Di Biase, C.; Malova, M.; Parodi, A.; Minghetti, D.; Traggiai, C.; Uccella, S.; Boeri, L.; Morana, G.; et al. Early Pain Exposure Influences Functional Brain Connectivity in Very Preterm Neonates. *Front. Neurosci.* 2019, 13, 899. [CrossRef] [PubMed]

42. Vinalli, J.; Miller, S.P.; Bjornson, B.H.; Fitzpatrick, K.P.; Poskitt, K.J.; Brant, R.; Synnes, A.R.; Cepeda, I.L.; Grunau, R.E. Invasive procedures in preterm children: Brain and cognitive development at school age. *Pediatrics* 2014, 133, 412–421. [CrossRef] [PubMed]

43. Committee on Fetus and Newborn and Section on Anesthesiology and Pain Medicine. Prevention and Management of Procedural Pain in the Neonate: An Update. *Pediatrics* 2016, 137, e20154271. [CrossRef]

44. American Academy of Pediatrics; Committee on Psychosocial Aspects of Child and Family Health; Task Force on Pain in Infants, Children, and Adolescents. The assessment and management of acute pain in infants, children, and adolescents. *Pediatrics* 2001, 108, 793–797. [CrossRef] [PubMed]

45. Valdieso Serna, A. Dolor agudo, analgesia y sedación en el niño (I): Detección y valoración. *An. Esp. Pediatr.* 1998, 48, 81–88. [CrossRef]

46. Baarslag, M.A.; Jhungoe, S.; Ista, E.; Allegaert, K.; Tibboel, D.; van Dijk, M. How often do we perform painful and stressful procedures in the paediatric intensive care unit? A prospective observational study. *Aust. Crit. Care.* 2019, 32, 4–10. [CrossRef]

47. Maxwell, L.G.; Fraga, M.V.; Malavolta, C.P. Assessment of pain in the newborn: An Update. *Clin. Perinatol.* 2019, 46, 693–707. [CrossRef]
77. Mangat, A.K.; Oei, J.L.; Chen, K.; Quah-Smith, I.; Schmölder, G.M. A Review of Non-Pharmacological Treatments for Pain Management in Newborn Infants. *Children* 2018, 5, 130. [CrossRef]

78. Shah, P.S.; Herbozo, C.; Aliwalas, L.L.; Shah, V.S. Breastfeeding or breast milk for procedural pain in neonates. *Cochrane Database Syst. Rev.* 2012, 12, CD004950. [CrossRef]

79. Collados-Gómez, L.; Ferrera-Camacho, P.; Fernández-Serrano, E.; Camacho-Vicente, V.; Flores-Herrero, C.; García-Pozo, A.M.; Jiménez-García, R. Randomised crossover trial showed that using breast milk or sucrose provided the same analgesic effect in preterm infants of at least 28 weeks. *Acta Paediatr.* 2018, 107, 436–441. [CrossRef]

80. Ou-Yang, M.C.; Chen, I.L.; Chen, C.C.; Chung, M.Y.; Chen, F.S.; Huang, H.C. Expressed breast milk for procedural pain in preterm neonates: A randomized, double-blind, placebo-controlled trial. *Acta Paediatr.* 2013, 102, 15–21. [CrossRef]

81. Stevens, B.; Yamada, J.; Ohlsson, A.; Haliburton, S.; Shorkey, A. Sucrose for analgesia in newborn infants undergoing painful procedures. *Cochrane Database Syst. Rev.* 2016, 7, CD001069. [CrossRef]

82. Gao, H.; Gao, H.; Xu, G.; Li, M.; Du, S.; Li, F.; Zhang, H.; Wang, D. Efficacy and safety of repeated oral sucrose for repeated procedural pain in neonates: A systematic review. *Int. J. Nurs. Stud.* 2016, 62, 118–125. [CrossRef] [PubMed]

83. Johnston, C.; Campbell-Yeo, M.; Disher, T.; Benoit, B.; Fernandes, A.; Steiner, D.; Inglis, D.; Zee, R. Skin-to-skin care for procedural pain in neonates. *Cochrane Database Syst. Rev.* 2017, 2, CD008435. [CrossRef] [PubMed]

84. Locatelli, C.; Bellieni, C.V. Sensorial saturation and neonatal pain: A review. *Acta Paediatr.* 2015, 104, 1564–1568. [CrossRef] [PubMed]

85. Li, T.; Fu, Y.; Yang, Y.; Zhou, Y.E. Control effect of virtual reality technology on procedural pain in children’s wound: A meta-analysis. *Medicine* 2022, 101, e30961. [CrossRef]

86. van der Heijden, M.J.; Oliai Araghi, S.; Jeekel, J.; Reiss, I.K.; Hunink, M.G.; van Dijk, M. Do hospitalized premature infants benefit from music interventions? A systematic review of randomized controlled trials. *PloS ONE* 2016, 11, e0161848. [CrossRef]

87. Chirico, G.; Cabano, R.; Villa, G.; Bigogno, A.; Ardesi, M.; Dionii, E. Randomised study showed that recorded maternal voices reduced pain in preterm infants undergoing heel lance procedures in a neonatal intensive care unit. *Acta Paediatr.* 2017, 106, 1564–1568. [CrossRef]

88. Juneau, A.L.; Aita, M.; Héon, M. Review and Critical Analysis of Massage Studies for Term and Preterm Infants. *Neonatal Netw.* 2015, 34, 165. [CrossRef]

89. Mitchell, A.J.; Hall, R.W.; Goliarnu, B.; Yates, C.; Williams, D.K.; Chang, J.; Anand, K.J. Does noninvasive electrical stimulation of acupuncture points reduce heelstick pain in neonates? *Acta Paediatr.* 2016, 105, 1434. [CrossRef]

90. Feng, H.; König, J.; König, T.; Muensterer, O. A randomized, placebo-controlled study of magnetic acupuncture for supplementary analgesia after laparoscopic appendectomy in children. *J. Pediatr. Surg.* 2022. [CrossRef]

91. Cerritelli, F.; Cicchitti, L.; Martelli, M.; Barlafante, G.; Renzetti, C.; Pizzolorusso, G.; Lupacchini, M.; D’Orazio, M.; Marinelli, B.; Cozzolino, V.; et al. Osteopathic manipulative treatment and pain in preterms: Study protocol for a randomized controlled trial. *Trials* 2015, 16, 84. [CrossRef]

92. Gray, L.; Garza, E.; Zageris, D.; Heilman, K.J.; Porges, S.W. Prevention and treatment of neonatal pain. *Sucrose and warmth for procedural pain in preterm neonates of at least 28 weeks. Acta Paediatr.* 2018, 107, 436–441. [CrossRef]

93. Shah, P.S.; Herbozo, C.; Aliwalas, L.L.; Shah, V.S. Breastfeeding or breast milk for procedural pain in neonates. *Acta Paediatr.* 2013, 102, 15–21. [CrossRef]

94. Stevens, B.; Yamada, J.; Ohlsson, A.; Haliburton, S.; Shorkey, A. Sucrose for analgesia in newborn infants undergoing painful procedures. *Cochrane Database Syst. Rev.* 2016, 7, CD001069. [CrossRef]

95. Saini, A.; Maher, K.O.; Deshpande, S.R. Nonopioid analgesics for perioperative and cardiac surgery pain in children: Current evidence and knowledge gaps. *Ann. Pediatr. Cardiol.* 2020, 13, 46–55. [CrossRef]

96. Zhu, A.; Benzon, H.A.; Anderson, T.A. Evidence for the Efficacy of Systemic Opioid-Sparing Analgesics in Pediatric Surgical Populations: A systematic review. *Anesth. Analg.* 2017, 125, 1569–1587. [CrossRef]

97. Poonai, N.; Zhu, R. Analgesia for Children in Acute Pain in the Post-codeine Era. *Curr. Pediatr. Rev.* 2015, 13, e607. [CrossRef]

98. Turner, A.D.; Sullivan, T.; Drury, K.; Hall, T.A.; Williams, C.N.; Guiliams, K.P.; Murphy, S.; Iqbal O’Meara, A.M. Cognitive Dysfunction After Analgesia and Sedation: Out of the Operating Room and Into the Pediatric Intensive Care Unit. *Front. Behav. Neurosci.* 2021, 15, 713668. [CrossRef]

99. Berde, C.B.; Sethna, N.F. Drug therapy: Analgesics for the treatment of pain in children. *N. Engl. J. Med.* 2002, 347, 1094–1103. [CrossRef]

100. Saini, A.; Maher, K.O.; Deshpande, S.R. Nonopioid analgesics for perioperative and cardiac surgery pain in children: Current evidence and knowledge gaps. *Ann. Pediatr. Cardiol.* 2020, 13, 46–55. [CrossRef]

101. Valeri, B.O.; Holsti, L.; Linhares, M.B.M. Neonatal pain and developmental outcomes in children born preterm: A systematic review. *Clin. J. Pain* 2015, 31, 355–362. [CrossRef]

102. Zwicker, J.G.; Miller, S.P.; Grunau, R.E.; Chau, V.; Brant, R.; Studholme, C.; Liu, M.; Synnes, A.; Poskitt, K.J.; Stiver, M.L.; et al. Smaller Cerebellar Growth and Poorer Neurodevelopmental Outcomes in Very Preterm Infants Exposed to Neonatal Morphine. *J. Pediatr.* 2016, 172, 81–87.e2. [CrossRef] [PubMed]
130. van Dijk, M.; Tibboel, D. Update on pain assessment in sick neonates and infants. *Pediatr. Clin. N. Am.* **2012**, *59*, 1167–1181. [CrossRef]

131. Ventafridda, V.; Saita, L.; Ripamonti, C.; De Conno, F. WHO guidelines for the use of analgesics in cancer pain. *React. Int. J. Tissue* **1985**, *7*, 93–96.